Boeing’s Demolition of a California Nuclear Testing Facility Has Nearby Families Worried About Cancer

Inside Climate News•Fri, Oct 23, 2026, 09:21 PM•2 min read

Boeing has almost completed the demolition of five buildings at its infamous Santa Susana Field Laboratory in Southern California, even as concerns mount among nearby families about potential health harms. The buildings at the former Rocketdyne facility—where one of the worst nuclear meltdowns i...

Source: [Inside Climate News](https://insideclimatenews.org/news/23102026/boeings-demolition-of-nuclear-facility-cancer/)

📰 Read Full Story

This is an aggregated headline summary. For the complete report, visit the original publisher.

Continue Reading at Inside Climate News ↗

#health #boeing #demolition #california #nuclear #facility #nearby #families #buildings

More Headlines

HealthE! Online• 24m ago

Eric Dane Ignored This Early ALS Symptom Before Diagnosis

The late Eric Dane is shedding light on the beginning of his battle with ALS. Months before the Grey’s Anatomy star—who died in February—was diagnosed with amyotrophic lateral sclerosis, he...

FinanceInvesting.com• 40m ago

Terawulf increases revolving credit facility to $400 million with amendment

Developing story — details emerging. Check the source link for the latest updates.

Technology9to5Google• 2h ago

Google Health 5.11 rolling out with Fitbit Air Health Guardian, improved sleep tracking, & more

Google Health 5. 11 is rolling out this week as a rather big update for Fitbit trackers and the Pixel Watch.

HealthSeeking Alpha• 4h ago

Moderna: Data Leak Brings Us No Closer To Truth About Cancer Vaccine

Developing story — details emerging. Check the source link for the latest updates.

HealthMarketWatch• 4h ago

The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.

HealthNBC News• 4h ago

Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial

Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.